Matching Items (4)
Filtering by

Clear all filters

Description
Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeutics on the nanometer scale can cross the blood-brain barrier and enter the parenchyma. Developing protein-based therapeutics is attractive for a number of reasons, yet, the production pipeline for high yield and consistent bioactive recombinant proteins remains

Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeutics on the nanometer scale can cross the blood-brain barrier and enter the parenchyma. Developing protein-based therapeutics is attractive for a number of reasons, yet, the production pipeline for high yield and consistent bioactive recombinant proteins remains a major obstacle. Previous studies for recombinant protein production has utilized gram-negative hosts such as Escherichia coli (E. coli) due to its well-established genetics and fast growth for recombinant protein production. However, using gram-negative hosts require lysis that calls for additional optimization and also introduces endotoxins and proteases that contribute to protein degradation. This project directly addressed this issue and evaluated the potential to use a gram-positive host such as Brevibacillus choshinensis (Brevi) which does not require lysis as the proteins are expressed directly into the supernatant. This host was utilized to produce variants of Stock 11 (S11) protein as a proof-of-concept towards this methodology. Variants of S11 were synthesized using different restriction enzymes which will alter the location of protein tags that may affect production or purification. Factors such as incubation time, incubation temperature, and media were optimized for each variant of S11 using a robust design of experiments. All variants of S11 were grown using optimized parameters prior to purification via affinity chromatography. Results showed the efficiency of using Brevi as a potential host for domain antibody production in the Stabenfeldt lab. Future aims will focus on troubleshooting the purification process to optimize the protein production pipeline.
ContributorsEmbrador, Glenna Bea Rebano (Author) / Stabenfeldt, Sarah (Thesis director) / Plaisier, Christopher (Committee member) / Harrington Bioengineering Program (Contributor, Contributor) / Barrett, The Honors College (Contributor)
Created2019-05
164830-Thumbnail Image.png
Description

Traumatic brain injury (TBI) is defined as an injury to the head that disrupts normal brain function. TBI has been described as a disease process that can lead to an increased risk for developing chronic neurodegenerative diseases, like frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). A pathological hallmark

Traumatic brain injury (TBI) is defined as an injury to the head that disrupts normal brain function. TBI has been described as a disease process that can lead to an increased risk for developing chronic neurodegenerative diseases, like frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). A pathological hallmark of FTLD and a hallmark of ALS is the nuclear mislocalization of TAR DNA Binding Protein 43 (TDP-43). This project aims to explore neurodegenerative effects of TBI on cortical lesion area using immunohistochemical markers of TDP-43 proteinopathies. We analyzed the total percent of NEUN positive cells displaying TDP-43 nuclear mislocalization. We found that the percent of NEUN positive cells displaying TDP-43 nuclear mislocalization was significantly higher in cortical tissue following TBI when compared to the age-matched control brains. The cortical lesion area was analyzed for each injured brain sample, with respect to days post-injury (DPI), and it was found that there were no statistically significant differences between cortical lesion areas across time points. The percent of NEUN positive cells displaying TDP-43 nuclear mislocalization was analyzed for each cortical tissue sample, with respect to cortical lesion area, and it was found that there were no statistically significant differences between the percent of NEUN positive cells displaying TDP-43 nuclear mislocalization, with respect to cortical lesion area. In conclusion, we found no correlation between the percent of cortical NEUN positive cells displaying TDP-43 nuclear mislocalization with respect to the size of the cortical lesion area.

ContributorsWong, Jennifer (Author) / Stabenfeldt, Sarah (Thesis director) / Bjorklund, Reed (Committee member) / Barrett, The Honors College (Contributor) / Harrington Bioengineering Program (Contributor)
Created2022-05
163463-Thumbnail Image.png
Description

Annually approximately 1.5 million Americans suffer from a traumatic brain injury (TBI) increasing the risk of developing a further neurological complication later in life [1-3]. The molecular drivers of the subsequent ensuing pathologies after the initial injury event are vast and include signaling processes that may contribute to neurodegenerative diseases

Annually approximately 1.5 million Americans suffer from a traumatic brain injury (TBI) increasing the risk of developing a further neurological complication later in life [1-3]. The molecular drivers of the subsequent ensuing pathologies after the initial injury event are vast and include signaling processes that may contribute to neurodegenerative diseases such as Alzheimer’s Disease (AD). One such molecular signaling pathway that may link TBI to AD is necroptosis. Necroptosis is an atypical mode of cell death compared with traditional apoptosis, both of which have been demonstrated to be present post-TBI [4-6]. Necroptosis is initiated by tissue necrosis factor (TNF) signaling through the RIPK1/RIPK3/MLKL pathway, leading to cell failure and subsequent death. Prior studies in rodent TBI models report necroptotic activity acutely after injury, within 48 hours. Here, the study objective was to recapitulate prior data and characterize MLKL and RIPK1 cortical expression post-TBI with our lab’s controlled cortical impact mouse model. Using standard immunohistochemistry approaches, it was determined that the tissue sections acquired by prior lab members were of poor quality to conduct robust MLKL and RIPK1 immunostaining assessment. Therefore, the thesis focused on presenting the staining method completed. The discussion also expanded on expected results from these studies regarding the spatial distribution necroptotic signaling in this TBI model.

ContributorsHuber, Kristin (Author) / Stabenfeldt, Sarah (Thesis director) / Brafman, David (Committee member) / Barrett, The Honors College (Contributor) / Harrington Bioengineering Program (Contributor) / School of Molecular Sciences (Contributor)
Created2022-05
Description
Traumatic brain injury (TBI) poses a significant global health concern with substantial health and economic consequences. Patients often face significant consequences after injury, notably persistent cognitive changes and an increased risk of developing neurodegenerative disease later in life. Apart from the immediate insult, the resulting inflammatory response can lead to

Traumatic brain injury (TBI) poses a significant global health concern with substantial health and economic consequences. Patients often face significant consequences after injury, notably persistent cognitive changes and an increased risk of developing neurodegenerative disease later in life. Apart from the immediate insult, the resulting inflammatory response can lead to neuroinflammation, oxidative stress, tissue death, and long-term neurodegeneration. Microglia and astrocytes play critical roles in these inflammatory processes, emphasizing the unmet need for targeted therapies. Vaccine formulations consisting of poly (a-ketoglutarate) (paKG) microparticles (MPs) encapsulating PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one) and myelin proteolipid protein (PLP) were developed for prior studies and have demonstrated the production of antigen-specific adaptive T-cell responses in the brain, spleen, and lymph nodes of mice, suggesting that these formulations may be able to prevent neuronal inflammation in mice after TBI. The vaccine efficacy was further evaluated through the image analysis of immunohistochemically stained brain tissue sections from naive, saline, and paKG(PFK15+PLP) MPs or paKG(PFK15) MPs treated mice. Though microglia (Iba1), astrocytes (GFAP) and CD86 were visualized in this method, only Iba1 was found to be significantly reduced in the contralateral hemisphere for paKG(PFK15+PLP) MPs and paKG(PFK15) MPs groups when compared to naive (p=0.0373 and p=0.0186, respectively). However, the naive group also showed an unexpectedly high level of CD86 after thresholding (compared to the TBI groups), indicating flaws were present in the analysis pipeline. Challenges of the image analysis process included thresholding setting optimization, folded tissues, bubbles, and saturated punctate signal. These issues may have impacted data accuracy, underscoring the need for rigorous optimization of experimental techniques and imaging methodologies when evaluating the therapeutic potential of the vaccines in mitigating TBI-induced neuroinflammation. Thus, future analyses should consider microglial morphology and employ more accurate thresholding in FIJI/ImageJ to better measure cellular activation and the overall positive signal.
ContributorsSundem, Andrea (Author) / Stabenfeldt, Sarah (Thesis director) / Willingham, Crystal (Committee member) / Barrett, The Honors College (Contributor) / Harrington Bioengineering Program (Contributor)
Created2024-05